# AutoReviewer Report

> Calibration warning: this run reproduces the Nature pipeline structure, but substitutes
> DeepSeek V4 Flash for the paper's validated o4-mini model. Its scores are not human-calibrated.

- Paper: B088.txt
- Model: deepseek-v4-flash
- Final decision: **Reject**
- Overall: **4/10**
- Confidence: **4/5**
- Independent decisions: {'Accept': 0, 'Reject': 5}
- Estimated API cost: **$0.013940**

## Final Meta-review

The paper proposes MCCE, a hybrid framework for multi-objective discrete optimization (demonstrated on molecular design) that combines a frozen closed-source LLM (GPT-4o/Gemini) for global exploration with a lightweight trainable local LLM (Qwen2.5-7B) for local adaptation. The local model is periodically updated using Direct Preference Optimization (DPO) on preference pairs constructed from successful evolutionary trajectories via a similarity-based data synthesis pipeline. Experiments on a five-objective drug-design benchmark (QED, SA, DRD2, GSK3β, JNK3) report higher hypervolume and top-k scores than several single-model and co-evolution baselines, suggesting that experience-driven learning improves optimization performance.

### Scores

| Dimension | Final | Five-review mean | SD | Range |
|---|---:|---:|---:|---:|
| Originality | 3 | 3.000 | 0.000 | 3-3 |
| Quality | 2 | 2.000 | 0.000 | 2-2 |
| Clarity | 2 | 2.200 | 0.400 | 2-3 |
| Significance | 2 | 2.400 | 0.490 | 2-3 |
| Soundness | 2 | 2.000 | 0.000 | 2-2 |
| Presentation | 2 | 2.000 | 0.000 | 2-2 |
| Contribution | 2 | 2.000 | 0.000 | 2-2 |
| Overall | 4 | 4.000 | 0.000 | 4-4 |
| Confidence | 4 | 3.400 | 0.490 | 3-4 |

### Strengths

- The idea of coupling a frozen API-based LLM with a trainable local model in an evolutionary loop is novel, timely, and directly addresses the limitation that closed-source models cannot internalize experience.
- The systematic comparison of SFT, RL, and DPO as training paradigms for the local model provides practical insight, and the similarity-based data synthesis mechanism is a thoughtful attempt to reduce distribution shift and contradictory preference pairs.
- Extending the benchmark to five objectives is more realistic than prior three-objective studies, and the authors provide a clear conceptual framework that could generalize to other discrete optimization problems.

### Weaknesses

- The claim of state-of-the-art performance is not substantiated: strong related LLM-based evolutionary baselines such as ExLLM and MoLLEO are not included in the experimental comparisons.
- No statistical significance tests or confidence intervals are reported; many metrics have overlapping standard deviations, making the observed improvements unreliable.
- The 'co-evolution' claim is overstated: the closed-source LLM is frozen and does not update, so only the local model truly learns; the role of the 'dpo_coevolve:api' result is unclear and not properly isolated from population-level effects.
- Key implementation details are missing or deferred to an incomplete appendix: exact scalarization for multi-objective scores, hyperparameters (β, learning rate, update frequency f, DPO dataset size), population size, selection method, and computational cost (API calls, training time) are not specified.
- The DPO-trained model exhibits lower validity (0.820 vs 0.902) and lower diversity/uniqueness compared to the frozen GPT-4o baseline, a practically important trade-off for drug design that is not discussed or mitigated.
- The framework is evaluated on only a single molecular-design task; the claimed broad applicability to other discrete optimization domains is unsupported.
- The paper has presentation issues: redacted references, typos in the appendix prompt (e.g., 'SIMLES', garbled 'GSK30̆3b2'), and unclear definitions of several metrics (Top1F, Top10F, Top100AUC, duplicate columns) hurt reproducibility and clarity.

### Questions

- How exactly is the multi-objective scalarized score computed for constructing DPO preference pairs and for reporting Top1F/Top10F/Top100AUC? Are all five objectives weighted equally?
- What does 'dpo_coevolve:api' measure, given that the API model is frozen? Does it evaluate the frozen model on the evolved population, or is there an adaptation mechanism that was not described?
- What are the exact hyperparameters used in main experiments (update frequency f, DPO dataset size |D|, β, learning rate, number of training steps, similarity quantile α) and how were they chosen?
- Are the observed hypervolume improvements statistically significant after appropriate multiple-testing correction? Please provide p-values or confidence intervals.
- Why are no direct comparisons made to ExLLM, MoLLEO, or other strong LLM-based molecular optimization baselines?
- Why does DPO training reduce validity and diversity, and does the framework include any post-hoc filtering or repair step to address this?
- What is the total computational cost (number of API calls, local training FLOPs, wall-clock time) compared to the single-model baselines, and are compute budgets matched across methods?
- How sensitive is the similarity-based data synthesis to the choice of alpha, similarity intervals, and fingerprint metric? Are there ablations isolating each component?

### Limitations

- Evaluation is limited to one domain (molecular design); the claimed generality to other discrete optimization problems is not demonstrated empirically.
- The method relies on proprietary closed-source API models, which limits reproducibility, introduces cost/latency, and entails non-deterministic behavior that is not analyzed.
- The frozen LLM does not truly co-evolve via parameter updates; the collaboration is asymmetrical, and the paper does not rigorously quantify the contribution of each model's evolving role.
- The DPO training objective uses a scalarized multi-objective score, which may obscure important trade-offs among the individual objectives.
- No statistical significance tests or robustness analyses are provided, so the stability of the reported improvements across runs is unknown.
- Potential dual-use concerns of improved small-molecule drug design are not discussed.

### Ethics

Ethical concerns flagged: **False**

## Usage and Cost

- Requests: 6
- Prompt tokens: 69,131
- Cache-hit prompt tokens: 4,096
- Cache-miss prompt tokens: 65,035
- Completion tokens: 17,226
- Reasoning tokens reported: 10,159
- Total tokens: 86,357
- Estimated total: $0.01393965

Full individual reviews and raw JSON responses are in `review_bundle.json`.
